Evidence map›Paper›PMID 41756998›Full record

ArticlebioRxiv : the preprint server for biology2026

WISP1 drives a mechanically active immune modulatory and proliferative cardiac myofibroblast state.

Sharon Parkins, Sarah R Anthony, Teagan K Goldsworthy, Akanksha Nigam, Neva C Schehl, Robert M Jaggers, Daniel A Kasprovic, Lisa C Green, Onur Kanisicak, Michael Tranter

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sharon ParkinsDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, OH.ORCID 0000-0003-2279-1598
Sarah R AnthonyDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, OH.ORCID 0000-0002-6230-8188
Teagan K GoldsworthyDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, OH.
Akanksha NigamDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, OH.
Neva C SchehlDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, OH.
Robert M JaggersDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH.ORCID 0000-0001-9613-7359
Daniel A KasprovicDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, OH.
Lisa C GreenDivision of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0002-1164-6611
Onur KanisicakDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH.ORCID 0000-0002-8393-4874
Michael TranterDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, OH.ORCID 0000-0002-0609-3717

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Understanding Cardiovascular Disease MechanismsT32HL125204 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Evangelia G Kranias, Jeffery D Molkentin · 2015 to 2026
$3.4M
Functional and mechanistic delineation of HuR-Wisp1 signaling on myofibroblast activityR01HL166326 · NHLBI · UNIVERSITY OF CINCINNATI · PI Onur Kanisicak, Michael Tranter · 2023 to 2026
$2.6M
Regulators of extracellular matrix production during cardiac development and diseaseR01HL148598 · NHLBI · UNIVERSITY OF CINCINNATI · PI KANISICAK, ONUR · 2020 to 2024
$2.0M
HuR-Wisp1 signaling in cardiac fibroblastsF31HL170636 · NHLBI · UNIVERSITY OF CINCINNATI · PI PARKINS, SHARON · 2023 to 2024
$97k
NCI NIH HHS P30 CA016058NHLBI NIH HHS F31 HL170636NHLBI NIH HHS R01 HL148598NHLBI NIH HHS R01 HL166326NHLBI NIH HHS T32 HL125204
6 · The paper itself

Abstract

Pathological cardiac remodeling is driven by the proliferation and differentiation of resident fibroblasts into active myofibroblasts and results in excessive extracellular matrix (ECM) deposition and tissue stiffening. Expression of the matricellular protein WISP1 has previously been shown to be increased with cardiac fibrosis and promote myofibroblast activity, but the mechanisms by which this occurs remain unknown. Primary cardiac fibroblasts were isolated from adult mouse hearts and treated with recombinant WISP1 or TGFβ1 both alone and in combination to determine the functional role of the matricellular protein WISP1 in driving cardiac myofibroblast activity. WISP1 significantly increased alpha-smooth muscle actin and collagen type I expression, total collagen secretion, collagen gel contractility, and wound healing equally in fibroblasts from both male and female mice. However, WISP1 alone failed to induce expression of periostin, a hallmark myofibroblast marker, suggesting the resulting WISP1-dependent cell phenotype is unique and/or acting through non-canonical pathways. Indeed, inhibition of P38 MAPK completely ablated the WISP1-dependent increase in αSMA and collagen expression, while having little to no impact on TGFβ1-dependent expression of myofibroblast marker genes. We next employed a multi-omics approach to define the functional impact of WISP1 on fibroblast cell-state within the transcriptome, cytosolic, and secreted ECM proteome. RNA-seq results show that WISP1 broadly promotes the expression of proliferative and immune modulatory genes at the transcriptomic level, while having very little impact on traditional myofibroblast and ECM modifying gene expression programs. At the proteome level, WISP1 was again a much weaker mediator of traditional myofibroblast and ECM proteins. However, in agreement with RNA-seq data, we observed a strong WISP1-dependent enrichment for proliferation-associated proteins in the cytosolic proteome and inflammation-associated proteins in the ECM proteome. Interestingly, WISP1 also showed a context-dependent response with TGFβ1, suggesting a more complex and yet to be elucidated signaling interaction between these independent mediators of myofibroblast activity. In conclusion, our data suggests that WISP1 promotes a unique proliferative and immune-modulatory myofibroblast phenotype.

Indexed as

cardiac fibrosisCCN4extracellular matrix remodelingFibroblastinflammatory signalingWISP1

Identifiers

PMID41756998
PMCPMC12934971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.